Completed PHASE1 INTERVENTIONAL 6-arm NCT02654093

A Drug-drug Interaction Study of DP-R213

A Randomized, Open-label, Single-dose, 3-period, 6-sequence Crossover Study to Evaluate the Safety and the Pharmacokinetics After Oral Concurrent Administration of Raloxifene, Cholecalciferol in Healthy Korean Male Subjects

Sponsor: Alvogen Korea

Conditions Healthy

Interventions Cholecalciferol Cholecalciferol and Raloxifene co-administration Raloxifene

Updated 6 times since 2017 Last updated: Mar 10, 2016 Started: Jan 31, 2016 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02654093, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Alvogen Korea, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alvogen Korea

Data source: Alvogen Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jung-gu, South Korea